Log in to your Inderes Free account to see all free content on this page.
Vimian Group
33.35 SEK 0%4 investors are following this company
Vimian Group is a group active in animal health. Through its subsidiaries, the company delivers medicines and technical solutions to veterinarians, laboratories, and pet owners. The products include, for example, drugs with associated clinical research and digital platforms for veterinary clinics. The company operates worldwide and is headquartered in Stockholm.
Revenue
3.69B
EBIT %
12.44 %
P/E
149.77
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
VIMIAN
Daily low / high price
32.8 / 33.45
SEK
Market cap
17.42B SEK
Turnover
3.01M SEK
Volume
91K
Latest videos
Financial calendar
Interim report
15.08.2024
Interim report
24.10.2024
Annual report
13.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Fidelio Vet Holding | 56.8 % | 58.1 % |
Handelsbanken Funds | 4.8 % | 4.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Conversion of C-shares in Vimian Group AB
Vimian reaches settlement agreement with one of the main sellers of VOI in the previously announced indemnification process relating to the US patent dispute
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Press release from the Annual General Meeting in Vimian Group AB (publ) on 22 May 2024
![Vimian Group, Investor Day, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/aad82800-958b-4dae-9175-4172ebd85cc1.png)
Vimian Group, Investor Day, 2024
![Vimian Group, Audiocast with teleconference, Q1, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/46d12261-4784-489b-8ebc-274e162e507e.png)
Vimian Group, Audiocast with teleconference, Q1, 2024
Vimian’s Interim Report for the first quarter of 2024
Invitation to Vimian’s Interim Report for the first quarter of 2024
Notice of Annual General Meeting in Vimian Group AB (publ)
Vimian publishes Annual Report and Sustainability Report for 2023
Vimian announces final outcome in the oversubscribed rights issue
Vimian publishes prospectus regarding the rights issue
![Vimian Group, Audiocast with teleconference, 2024](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/2d18d050-c6b0-4bb8-916c-5ff6a53229c4.png)
Vimian Group, Audiocast with teleconference, 2024
Vimian resolves on a rights issue of up to approximately SEK 1,633 million to finance future M&A, announces new financial targets and declares its intention to change listing venue
Vimian announces new financial targets
Magnus Welander proposed as new Chairman of the Board in Vimian Group
Vimian reaches settlement agreement with one of the sellers in the indemnification process relating to the US patent dispute
![Vimian Group, Audiocast with teleconference, Q4, 2023](https://www.inderes.se/cdn-cgi/image/format=auto,width=640,height=358,quality=90,fit=cover/https://content.inderes.se/assets/df311293-5391-4317-aada-97ffe9dc803e.png)